Vera Therapeutics (VERA) to Post Earnings on Tuesday

Vera Therapeutics (NASDAQ:VERA) is projected to announce its Q2 2026 results before the market opens on Tuesday, August 4th. Analysts expect the company to post earnings of ($1.60) per share and revenue of $1.2810 million for the quarter. Investors may review the information on the company’s upcoming Q2 2026 earning report page for the latest details on the call scheduled for Wednesday, August 5, 2026 at 12:30 PM ET.

Vera Therapeutics (NASDAQ:VERA) last announced its quarterly earnings results on Thursday, May 7th. The company reported ($1.69) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.33) by ($0.36). During the same quarter in the previous year, the company posted ($0.81) earnings per share. On average, analysts expect Vera Therapeutics to post $-6 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

Vera Therapeutics Price Performance

Shares of NASDAQ VERA traded down $1.60 during midday trading on Tuesday, reaching $33.58. 536,569 shares of the company traded hands, compared to its average volume of 1,368,754. Vera Therapeutics has a 12 month low of $19.07 and a 12 month high of $56.05. The company has a debt-to-equity ratio of 0.15, a quick ratio of 13.64 and a current ratio of 13.64. The stock’s 50-day simple moving average is $37.02 and its 200-day simple moving average is $40.01. The firm has a market cap of $2.41 billion, a PE ratio of -6.05 and a beta of 0.92.

Wall Street Analyst Weigh In

VERA has been the topic of several research analyst reports. Wedbush upped their price objective on shares of Vera Therapeutics from $35.00 to $43.00 and gave the stock a “neutral” rating in a research note on Wednesday, July 8th. Needham & Company LLC set a $125.00 price objective on Vera Therapeutics in a research report on Wednesday, July 8th. Jefferies Financial Group restated a “buy” rating and set a $60.00 target price on shares of Vera Therapeutics in a report on Tuesday, June 2nd. William Blair reiterated an “outperform” rating on shares of Vera Therapeutics in a research report on Tuesday, June 2nd. Finally, The Goldman Sachs Group reissued a “buy” rating and set a $90.00 price objective on shares of Vera Therapeutics in a report on Tuesday, June 2nd. Eleven investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $84.58.

Insider Activity at Vera Therapeutics

In related news, CEO Marshall Fordyce sold 46,250 shares of Vera Therapeutics stock in a transaction that occurred on Tuesday, July 7th. The shares were sold at an average price of $42.30, for a total transaction of $1,956,375.00. Following the transaction, the chief executive officer owned 151,994 shares of the company’s stock, valued at $6,429,346.20. This trade represents a 23.33% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders sold 83,250 shares of company stock valued at $3,337,770. Corporate insiders own 15.90% of the company’s stock.

Institutional Trading of Vera Therapeutics

Several hedge funds have recently added to or reduced their stakes in the business. Nebula Research & Development LLC acquired a new stake in shares of Vera Therapeutics during the second quarter worth about $463,000. AQR Capital Management LLC bought a new position in Vera Therapeutics in the fourth quarter valued at approximately $400,000. Mariner LLC bought a new stake in shares of Vera Therapeutics during the fourth quarter worth $394,000. Odyssean LLC bought a new stake in shares of Vera Therapeutics during the fourth quarter worth $380,000. Finally, Massar Capital Management LP acquired a new stake in shares of Vera Therapeutics during the second quarter worth $377,000. Institutional investors and hedge funds own 99.21% of the company’s stock.

About Vera Therapeutics

Vera Therapeutics is a clinical-stage biotechnology company focused on developing novel immunotherapies that harness the body’s own regulatory T cells to treat autoimmune and inflammatory diseases. By leveraging a proprietary protein engineering platform, the company designs Treg-selective cytokine variants intended to restore immune balance and provide targeted, disease-modifying effects. Its pipeline comprises multiple preclinical and clinical candidates aimed at indications characterized by chronic inflammation and autoimmunity.

Founded in 2018 and headquartered in Cambridge, Massachusetts, Vera Therapeutics collaborates with leading academic and research institutions to advance its development programs.